Regeneron’s Veopoz Receives FDA Go-Ahead

Image Credit: Adobe Stock Images/Aquir

Regeneron Pharmaceuticals has confirmed the FDA approval of Veopoz (pozelimab-bbfg), designated for adult and pediatric patients one year of age and older with chaple disease, also known as CD55-deficient protein-losing enteropathy. According to a company press release, the treatment is the first and only one indicated for the potentially life-threatening gastrointestinal and cardiovascular disease.

“As the first-ever treatment for chape, Veopoz is a testament to our commitment to uncovering genetic insights and applying them to the development of effective treatments for patients in need – regardless of the prevalence of their disease,” said George D. Yancopoulos, MD, PhD, board co-chair, president, chief scientific officer, Regeneron, as per the release. “Beyond chaple, we believe Veopoz has promise in a variety of complement-mediated diseases and are driving forward several clinical programs to explore its broader potential.”

Reference: VEOPOZ™ (POZELIMAB-BBFG) RECEIVES FDA APPROVAL AS THE FIRST TREATMENT FOR CHILDREN AND ADULTS WITH CHAPLE DISEASE. Regeneron. August 18, 2023. Accessed August 21, 2023.